{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jung YH"],"funding":["National Institute of Environmental Health Sciences","Intramural NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases"],"pagination":["5099-5122"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8317135"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64(8)"],"pubmed_abstract":["A known zwitterionic, heterocyclic P2Y<sub>14</sub>R antagonist <b>3a</b> was substituted with diverse groups on the central phenyl and terminal piperidine moieties, following a computational selection process. The most potent analogues contained an uncharged piperidine bioisostere, prescreened in silico, while an aza-scan (central phenyl ring) reduced P2Y<sub>14</sub>R affinity. Piperidine amide <b>11</b>, 3-aminopropynyl <b>19</b>, and 5-(hydroxymethyl)isoxazol-3-yl) <b>29</b> congeners in the triazole series maintained moderate receptor affinity. Adaption of 5-(hydroxymethyl)isoxazol-3-yl gave the most potent naphthalene-containing (<b>32</b>; MRS4654; IC<sub>50</sub>, 15 nM) and less active phenylamide-containing (<b>33</b>) scaffolds. Thus, a zwitterion was nonessential for receptor binding, and molecular docking and dynamics probed the hydroxymethylisoxazole interaction with extracellular loops. Also, amidomethyl ester prodrugs were explored to reversibly block the conserved carboxylate group to provide neutral analogues, which were cleavable by liver esterase, and in vivo efficacy demonstrated. We have, in stages, converted zwitterionic antagonists into neutral molecules designed to produce potent P2Y<sub>14</sub>R antagonists for in vivo application."],"journal":["Journal of medicinal chemistry"],"pubmed_title":["Structure-Activity Relationship of Heterocyclic P2Y&lt;sub&gt;14&lt;/sub&gt; Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres."],"pmcid":["PMC8317135"],"funding_grant_id":["ZIA ES102025","ZIAES102025","Z01 DK031116","ZIADK031116","ZIA DK031116"],"pubmed_authors":["Karcz TP","Wen Z","Bennett JM","Lieberman DI","Salmaso V","Phung NB","Gopinatth V","Jacobson KA","Chen Z","Randle JCR","Jung YH","Cook DN","Salvemini D"],"additional_accession":[]},"is_claimable":false,"name":"Structure-Activity Relationship of Heterocyclic P2Y&lt;sub&gt;14&lt;/sub&gt; Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres.","description":"A known zwitterionic, heterocyclic P2Y<sub>14</sub>R antagonist <b>3a</b> was substituted with diverse groups on the central phenyl and terminal piperidine moieties, following a computational selection process. The most potent analogues contained an uncharged piperidine bioisostere, prescreened in silico, while an aza-scan (central phenyl ring) reduced P2Y<sub>14</sub>R affinity. Piperidine amide <b>11</b>, 3-aminopropynyl <b>19</b>, and 5-(hydroxymethyl)isoxazol-3-yl) <b>29</b> congeners in the triazole series maintained moderate receptor affinity. Adaption of 5-(hydroxymethyl)isoxazol-3-yl gave the most potent naphthalene-containing (<b>32</b>; MRS4654; IC<sub>50</sub>, 15 nM) and less active phenylamide-containing (<b>33</b>) scaffolds. Thus, a zwitterion was nonessential for receptor binding, and molecular docking and dynamics probed the hydroxymethylisoxazole interaction with extracellular loops. Also, amidomethyl ester prodrugs were explored to reversibly block the conserved carboxylate group to provide neutral analogues, which were cleavable by liver esterase, and in vivo efficacy demonstrated. We have, in stages, converted zwitterionic antagonists into neutral molecules designed to produce potent P2Y<sub>14</sub>R antagonists for in vivo application.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-31T02:07:39.9Z","creation":"2025-04-04T23:03:23.554Z"},"accession":"S-EPMC8317135","cross_references":{"pubmed":["33787273"],"doi":["10.1021/acs.jmedchem.1c00164"]}}